Live feed08:00:00·7dPRReleasevia QuantisnowKyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 WeeksByQuantisnow·Wall Street's wire, on your screen.KYTX· Kyverna Therapeutics Inc.Health Care
